A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated ...

The familial cancer syndrome, von Hippel–Lindau (VHL) disease, characterized by a predisposition to renal cell carcinoma and certain other tumor types, is caused by mutational inactivation of the VHL ...

The gastrointestinal neuroendocrine tumors market is experiencing steady growth driven by increasing disease prevalence, improved diagnostic capabilities, and rising awareness of targeted therapies.

BERLIN -- Belzutifan (Welireg) induced durable responses in advanced pheochromocytoma or paraganglioma (PPGL) in a single-arm ...

RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety ...

People affected by Huntington’s disease could at last benefit from the first treatment to slow the fatal neurodegenerative condition. Scientists from University College London (UCL) found patients ...

Millions of adults in their 20s or older have coronary artery disease. But experts say the common condition doesn’t have to be an inevitable part of aging. There are steps you can take to reduce your ...

Scientists have discovered what could be a breakthrough in the treatment of Alzheimer’s disease. Over 7 million Americans are living with Alzheimer’s, which slowly erodes memory, cognitive skills and ...